CCR5 Antagonists — Out with the Old, In with the New?

In studies reported at the 2010 Retrovirus Conference, vicriviroc did not significantly improve an already-strong optimized background regimen, and a new CCR5 antagonist, TBR-652, was shown to have potent antiviral activity and several other favorable characteristics.

Maraviroc — the only currently licensed CCR5 antagonist — has proven effective in both treatment-naive and treatment-experienced patients but is hampered by twice-daily administration. At the 2010 Conference on Retroviruses and Opportunistic Infections, researchers described two related once-daily compounds that are in development: vicriviroc and newcomer TBR-652.

Vicriviroc

Vicriviroc has been studied for several years and was widely expected to be the next CCR5 antagonist licensed. However, data from the VICTOR-E3 and VICTOR-E4 trials, presented by Joseph Gathe, may present a roadblock [Abstract 54LB]. In these parallel trials, 721 patients with dual-class resistance or ≥6 months of antiretroviral exposure were randomized to receive an opti…

Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

CCR5 Antagonists — Out with the Old, In with the New?

Topics

Vicriviroc

Author